LUCD · XBRL financial data

Lucid Diagnostics financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LUCD's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	500	377	2,428	4,346	—
Revenue from contracts with customers	500	377	2,428	4,346	—
Cost of revenue	585	—	—	7,099	6,670
Cost of goods and services sold	—	100,000	—	—	—
Gross profit	(85)	377	—	—	—
Research and development	9,296	11,466	7,252	5,992	5,678
Selling, general and administrative	21	—	—	—	—
General and administrative	12,778	23,685	19,254	20,156	23,867
Total operating expenses	27,334	56,548	50,910	50,398	—
Operating income (loss)	(27,419)	(56,171)	(48,482)	(46,052)	(49,640)
Interest income	—	—	—	322	386
Interest expense	659	8	416	26	22
Other income (expense)	(659)	80	(4,184)	523	—
Income tax expense (benefit)	—	—	—	0	0
Net income (loss)	(28,078)	(56,171)	(52,666)	(45,529)	(58,010)
Earnings per share, basic USD per share	(1.51)	(1.55)	(1.26)	(1.05)	(0.69)
Earnings per share, diluted USD per share	—	(1.55)	(1.26)	(1.05)	—
Weighted average shares, basic thousands of shares	18,604	36,172	41,756	50,516	101,947
Weighted average shares, diluted thousands of shares	—	36,172	41,756	50,516	—

Fiscal years (LUCD's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	53,656	22,474	18,896	22,358	34,705
Accounts receivable	200	17	45	45	643
Inventory	—	111	278	341	353
Prepaid and other current assets	3,447	1,865	2,854	2,404	1,767
Total current assets	57,303	24,356	22,073	25,148	37,468
Property and equipment, net	971	1,592	1,334	1,062	809
Right-of-use asset	—	2,008	1,307	2,637	1,806
Total assets	58,999	32,509	27,270	30,715	40,445
Accounts payable	1,490	1,056	1,146	1,241	970
Accrued liabilities	—	—	—	2,829	2,719
Total current liabilities	4,260	8,425	29,382	23,524	28,582
Lease liability, non-current	—	1,037	199	1,800	927
Total liabilities	4,260	9,462	29,581	25,324	29,509
Accumulated deficit	(41,904)	(98,075)	(150,741)	(203,766)	(274,335)
Total stockholders' equity	54,739	23,047	(2,311)	5,391	10,936
Total liabilities and equity	58,999	32,509	27,270	30,715	40,445
Common shares outstanding (cover page) thousands of shares	37,433	43,394	48,245	66,969	176,946

Fiscal years (LUCD's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(28,078)	(56,171)	(52,666)	(45,529)	(58,010)
Stock-based compensation	9,599	13,859	5,762	4,183	—
Depreciation and amortization	4	1,936	2,499	1,167	872
Net cash from operating activities	(17,668)	(29,685)	(32,817)	(44,140)	(46,485)
Purchases of property and equipment	862	3,200	—	296	197
Net cash from investing activities	(862)	(4,108)	(221)	(646)	(197)
Proceeds from issuing common stock	—	1,807	—	—	—
Net cash from financing activities	72,075	2,611	29,460	48,248	59,029
Net change in cash	53,545	(31,182)	(3,578)	3,462	12,347

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Lucid Diagnostics	33,404	not reported	(11,297)*	203.2M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Apyx Medical	27,617	13,884	(3,490)*	42.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Encision	72	1,528	(127)*	16.9M	0.6 quarters	Q2 FY26 10-QSep 30, 2025
Accuray	40,623	100,919*	2,427*	119.4M	—	Q4 FY26 10-KJun 30, 2026
TELA Bio	30,424	19,291	(9,381)*	44.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
enVVeno Medical	2,585	not reported	(3,178)*	694,826	5.6 quarters	Q3 FY26 10-QSep 30, 2026
Fonar	53,650	26,472	1,580*	not reported	—	Q3 FY26 10-QMar 31, 2026
Spectral AI	14,000	3,524	(4,097)*	32.2M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Microbot Medical	3,152	241	(4,989)*	67.2M	13.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.